Matic Koželj
YOU?
Author Swipe
View article: The Incidence of IgG4-Related Disease in Slovenia—Single-Centre Experience
The Incidence of IgG4-Related Disease in Slovenia—Single-Centre Experience Open
Background: Data on the incidence of IgG4-related disease (IgG4-RD) are scarce. Our aim was to determine the incidence of IgG4-RD in a well-defined region. Methods: This retrospective study covered the Ljubljana region over the period from…
View article: Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres – prime time for decentralisation of inflammatory bowel disease care?
Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres – prime time for decentralisation of inflammatory bowel disease care? Open
Background With the increasing number of inflammatory bowel disease (IBD) patients, it is difficult to manage them within specialised IBD teams in academic medical centres: many are therefore treated in nonacademic IBD centres. It is uncle…
View article: Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease
Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease Open
Background and Objectives: The subcutaneous (SC) formulation of vedolizumab has proven to be effective for the maintenance of remission after intravenous induction. Little is known about the efficacy of switching from intravenous maintenan…
View article: P720 Drug survival of first-line biologics in inflammatory bowel disease: large single-centre experience from UR-CARE
P720 Drug survival of first-line biologics in inflammatory bowel disease: large single-centre experience from UR-CARE Open
Background The expanding therapeutic armamentarium for inflammatory bowel disease (IBD) has led to uncertainty about the optimal first-line biological therapy for a given patient. Given the paucity of dedicated head-to-head trials, treatme…
View article: P702 Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel Disease
P702 Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel Disease Open
Background Background: Subcutaneous (SC) formulation of vedolizumab (VDZ), a gut selective integrin antagonist used for treatment of inflammatory bowel disease (IBD), has proven effective and safe in clinical trials after intravenous (IV) …
View article: Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model
Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model Open
Ustekinumab is a monoclonal antibody used in Crohn’s disease (CD). Dose optimization in case of non-response and the role of pharmacokinetic–pharmacodynamic (PK-PD) monitoring remain unresolved dilemmas in clinical practice. We aimed to de…
View article: Natural History and Risk Stratification of Recurrent Crohn’s Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort Study
Natural History and Risk Stratification of Recurrent Crohn’s Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort Study Open
Background Prediction of endoscopic postoperative recurrence (POR) and prophylactic treatment based on clinical risk profile have thus far been inconclusive. This study aimed to examine the association between clinical risk profile and the…
View article: P180 Association between serum and tissue protein profiles in patients with active inflammatory bowel disease: the ASCERTAIN study
P180 Association between serum and tissue protein profiles in patients with active inflammatory bowel disease: the ASCERTAIN study Open
Background To facilitate personalised treatment of inflammatory bowel disease (IBD), biomarkers for disease entity and disease severity in easily accessible samples are required. Therefore, we aimed to (i) identify proteins that discrimina…
View article: Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease Open
Background The relationship between vedolizumab trough levels and combined endoscopic and clinical remission is unknown. Objective To compare vedolizumab trough levels in patients with and without combined remission within the first year o…
View article: P603 Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease
P603 Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease Open
Vedolizumab (VDZ) is an anti-integrin monoclonal antibody for the treatment of inflammatory bowel disease. There appears to be a positive correlation between drug levels and clinical outcomes, however, data on endoscopic outcomes are scarc…
View article: P632 Trough levels of golimumab at Week 6 predict drug retention rate in ulcerative colitis
P632 Trough levels of golimumab at Week 6 predict drug retention rate in ulcerative colitis Open
Real-life data on clinical efficacy and pharmacokinetics of golimumab in ulcerative colitis are scarce. We aimed to study clinical outcome and pharmacokinetics of golimumab in real-life settings and to identify biochemical and clinical pre…
View article: Success and safety of high infliximab trough levels in inflammatory bowel disease
Success and safety of high infliximab trough levels in inflammatory bowel disease Open
Objective: A prospective trial suggests target infliximab trough levels of 3–7 μg/mL, yet data on additional therapeutic benefits and safety of higher trough levels are scarce. Aim: To explore whether high infliximab trough levels (≥7 μg/m…